

Wednesday 17 August, 2016

**ASX announcement**

**Non-Renounceable Pro-Rata Rights Issue – Shortfall Notice**

Optiscan Imaging Limited (ASX: OIL) (“**Optiscan**” or “**the Company**”) is pleased to advise that the underwritten non-renounceable pro-rata Rights Issue of two (2) new share for every nine (9) shares held on the Record Date at an issue price of 2.5 cents (\$0.025) per share to raise \$1,415,777 before costs of the issue closed on 12 August 2016.

Optiscan received valid acceptances from shareholders for 22,078,044 shares (\$551,951.10).

The total shortfall under the Rights Issue was 34,546,874 shares (“Shortfall”).

All Shortfall shares are to be applied for by the underwriter Life Sciences Pty Ltd [ACN 606 378 410] (“**Life Sciences**”) and/or sub-underwriters in accordance with the terms of the underwriting.

The allotment and issue of shares to accepting shareholders is expected to occur in accordance with the updated timetable lodged as an announcement with ASX on 26 July 2016. Holding statements for the new shares will be despatched shortly thereafter.

This notice is given in accordance with Appendix 7A of the ASX Listing Rules.

**Planned expenditure of funds raised by the Rights Issue**

As set out in the Rights issue prospectus the Company intends to utilise the funds raised by the Rights Issue in connection with or ancillary to its existing projects and activities as set out below:

<i>Proposed use of funds</i>	\$	%
Cell 2 Live commercialisation	150,000	10.6%
2.4mm probe, including digital imaging and virtual biopsy	147,500	10.4%
Clinical sheath market development	50,000	3.5%
Carl Zeiss project	123,000	8.7%
General working capital and administrative costs	820,277	58.0%

<i>Proposed use of funds</i>	\$	%
<u>Costs of the issue</u>	<u>125,000</u>	<u>8.8%</u>
<b><u>TOTAL</u></b>	<b><u>1,415,777</u></b>	<b><u>100.0%</u></b>

Further details of the use of funds can be found in the Prospectus dated 22 July 2016 and lodged as an announcement with the ASX on 25 July 2016.

### **Compliance with listing rules**

The Company confirms that it is in compliance with the ASX Listing Rules and in particular ASX Listing Rule 3.1.

If you have any queries concerning the Rights Issue, or the action you are required to take to subscribe for New Shares, please contact your financial adviser or Mr Michael Corry, Company Secretary, on +61 3 9538 3398.

### **About Optiscan**

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging technologies for medical markets.

Michael Corry,  
Company Secretary



Michael Corry  
Company Secretary,  
Optiscan Imaging Limited